-
Better Buy: Procter & Gamble vs. Johnson & Johnson
Post on 9/22/16
-
McKesson Pharmacy Systems Launches Pharmaserv 7.5
Post on 9/21/16
-
Admera Health Expands its Next Generations Sequencing Based Pharmacogenomics Test with Update to PGxOne Plus
Post on 9/21/16
-
Abeona Therapeutics Licenses Next Generation AAV Gene Therapy Vector Platform from The University of North Carolina at Chapel Hill
Post on 9/21/16
-
Johnson & Johnson's Smart (Yet Surprising) Acquisition
Post on 9/21/16
-
Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday
Post on 9/21/16
-
Hepatitis B Foundation Launches Comprehensive New Website to Celebrate 25th Anniversary
Post on 9/20/16
-
Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016
Post on 9/20/16
-
Zynerba Pharmaceuticals Revaluation Imminent
Post on 9/20/16
-
Hemispherx Biopharma Regains Compliance with NYSE MKT Continued Listing Standards
Post on 9/19/16
-
Roka Bioscience Prices Private Placement of Preferred Stock and Warrants
Post on 9/18/16
-
Better Buy: Pfizer Inc. vs. AbbVie Inc.
Post on 9/16/16
-
5 Reasons Celgene Is a Buy
Post on 9/16/16
-
National Business Group on Health Honors Teva Pharmaceuticals with Best Employers for Healthy Lifestyles Award
Post on 9/15/16
-
Ferring Pharmaceuticals Recognized as the Nation’s Most Adoption-Friendly Workplace by Dave Thomas Foundation for Adoption
Post on 9/14/16
-
Why Pfizer's Stock Is a Big Gamble Right Now
Post on 9/14/16
-
A Video Conversation with Rick Birkmeyer, CEO of CD Diagnostics - Part III
Post on 9/21/16
-
A Video Conversation with Rick Birkmeyer, CEO of CD Diagnostics - Part II
Post on 9/19/16
-
Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer
Post on 9/14/16
-
A Video Conversation with Rick Birkmeyer, CEO of CD Diagnostics - Part I
Post on 9/15/16
-
Matinas BioPharma Completes Private Placement of $8.0 Million
Post on 9/13/16
-
Reproductive Medicine Associates of New Jersey to Offer Free Physicians' Webinar Series on Infertility
Post on 9/13/16
-
2 Companies Johnson & Johnson Should Consider Buying
Post on 9/12/16
-
3 All-or-Nothing Biotechs I'm Watching Like a Hawk
Post on 9/12/16
-
3 Stocks to Avoid in the Biotechnology Sector
Post on 9/12/16
Philadelphia
